Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon

doi:10.1016/0277-5379(89)90107-7

European Journal of Cancer and Clinical Oncology

Volume 25, Issue 10, October 1989, Pages 1475-1479

European Journal of ...

https://doi.org/10.1016/0277-5379(89)90107-7 Get rights and content

Abstract

In a randomized controlled study, 20 patients with malignant carcinoid tumors were included. Ten patients received streptozocin plus 5-fluorouracil for 6 months and another 10 human leukocyte interferon (IFN). After 6 months of treatment, an objective tumor response was noted in five of the patients treated with IFN (50%) but in none of the patients on chemotherapy. Stable disease was found in five patients (50%) on IFN treatment and four (40%) on chemotherapy. Progressive disease was noted in six of the patients (60%) receiving chemotherapy. A statistical analysis using the chi-square test showed a significantly higher proportion of responders and stable disease in the IFN treated group (P = 0.0039). Furthermore, three of eight patients who had previously received chemotherapy showed later on an objective response to IFN. The objective responses were mainly noted in decreased tumor markers; however, two patients also showed a significant reduction of tumor size. Subjective responses were noted in 72% of patients treated with interferon, but only in 9% of those treated with streptozocin plus 5-fluorouracil. The results indicate that interferon treatment is superior to the combination of streptozocin plus 5-fluorouracil. Considering both the therapeutic effects and adverse reactions, human leukocyte interferon is a promising alternative for treatment of patients with malignant carcinoid tumors.

References (17)

KG Wahlund et al.
Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column
Clin Chem Acta
(1981)
PS Schein et al.
Clinical antitumor activity and toxicity of streptozocin (NSC-8598)
Cancer
(1974)
D Chernicoff et al.
Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozocin
Cancer Treat Rep
(1979)
CG Moertel et al.
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome
Cancer Clin Trials
(1979)
K Öbert et al.
Cytotoxic treatment in patients with malignant carcinoid tumors; response to streptozocin alone or in combination with 5-FU
Acta Oncol
(1987)
K Öberg et al.
Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome
N Engl J Med
(1983)
K Öberg et al.
Treatment of malignant carcinoid tumors with human leucocyte interferon—long term results
Cancer Treat Rep
(1986)
L Grimelius
A silver nitrate stain for A2 cells in human pancreatic islets
Acta Soc Med Uppsala
(1968)

There are more references available in the full text version of this article.

Cited by (73)

Medical Management of Gastroenteropancreatic Neuroendocrine Tumors
2020, Surgical Oncology Clinics of North America
Role of Glycosylation in Modulating Therapeutic Efficiency of Protein Pharmaceuticals
2019, Protein Modificomics: From Modifications to Clinical Perspectives
Since the introduction of human insulin as a recombinant therapeutic protein, pharmaceutical proteins have emerged as potential drug candidates with a dramatic increase in their number. The major reasons for their promising therapeutic potential include higher activity, low toxicity, target specificity, and minimal nonspecific interactions/side reactions. However, poor physiochemical properties and rapid clearance has severely limited their utility. In order to overcome these shortcomings, advanced technological approaches have been established to design protein pharmaceuticals with improved shelf life, serum half-life, and activity. One such approach is glycoengineering, i.e., modulation of therapeutic properties of proteins by changing the sugar residues associated with these proteins. This is due to the fact that glycans do affect the therapeutic efficiency of protein drugs as they play a vital role in solubility, stability, immunogenicity, and half-life of protein drugs. Keeping in view the ability of glycans to efficiently modulate the therapeutic properties of protein pharmaceuticals, and also the rapid advancements in this emerging field of research, it will be interesting to provide an updated scenario of the effect of glycosylation on pharmacological properties of therapeutically important proteins. Future insights in this direction have also been highlighted.
Role of glycosylation in modulating therapeutic efficiency of protein pharmaceuticals
2019, Molecular Nutrition: Vitamins
Since the introduction of human insulin as a recombinant therapeutic protein, pharmaceutical proteins have emerged as potential drug candidates with a dramatic increase in their number. The major reasons for their promising therapeutic potential include higher activity, low toxicity, target specificity, and minimal nonspecific interactions/side reactions. However, poor physiochemical properties and rapid clearance has severely limited their utility. In order to overcome these shortcomings, advanced technological approaches have been established to design protein pharmaceuticals with improved shelf life, serum half-life, and activity. One such approach is glycoengineering, i.e., modulation of therapeutic properties of proteins by changing the sugar residues associated with these proteins. This is due to the fact that glycans do affect the therapeutic efficiency of protein drugs as they play a vital role in solubility, stability, immunogenicity, and half-life of protein drugs. Keeping in view the ability of glycans to efficiently modulate the therapeutic properties of protein pharmaceuticals, and also the rapid advancements in this emerging field of research, it will be interesting to provide an updated scenario of the effect of glycosylation on pharmacological properties of therapeutically important proteins. Future insights in this direction have also been highlighted.
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review
2017, Surgery (United States)
Liver transplantation to treat neuroendocrine tumors, especially in the setting of diffuse liver involvement not amenable to operative resection remains controversial. We sought to perform a systematic review of the current literature to summarize data on patients undergoing liver transplantation with neuroendocrine tumors liver metastases as the indication.
A systematic review was conducted in accordance to the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. Eligible studies were identified using 3 distinct databases through March 2017: Medline (PubMed), ClinicalTrials.gov, and Cochrane library, Cochrane Central Register of Controlled Trials using a search algorithm: “(neuroendocrine or NET) and transplantation and liver.”
From the 1,216 records retrieved, 64 studies were eligible. Overall, 4 studies presented data from registries, namely the European Liver Transplant Registry and the United Network for Organ Transplantation/Organ Procurement and Transplantation Network databases, 3 were multicenter studies. The largest cohort of data on patients undergoing liver transplantation for neuroendocrine tumors liver metastasis indication were from single center studies comprising a total of 279 patients. Pancreas was the primary tumor site for most patients followed by the ileum. Several studies reported that more than half of patients presented with synchronous disease (55.9% and 57.7%); in contrast, metachronous neuroendocrine tumors liver metastasis ranged from 17.7% to 38.7%. Overall, recurrence after liver transplantation ranged from 31.3% to 56.8%. Reported 1-, 3-, and 5-year overall survival was 89%, 69%, and 63%, respectively. Several prognostic factors associated with worse long-term survival including transplantation >50% liver tumor involvement, high Ki67, as well as a pancreatic neuroendocrine tumors versus gastrointestinal neuroendocrine tumors tumor location.
Liver transplantation may provide a survival benefit among patients with diffuse neuroendocrine tumors metastases to the liver. However, due to high recurrence rates, strict selection of patients is critical. Due to the scarcity of available grafts and the lack of level 1 evidence, the recommendations to endorse liver transplantation for extensive liver neuroendocrine tumors metastases warrants ongoing deliberations.
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
2016, Cancer Treatment Reviews
Citation Excerpt :
Multiple chemotherapy schedules were used across the 20 studies; all three randomised studies used IFN alone in the control arm [121–123]. The most commonly used drugs were 5-FU/capecitabine (12 studies; [121–124,126,128–130,134–136,139]) followed by alkylating agents such as streptozocin, temozolomide, dacarbazine, thalidomide or lomustine (10 studies; [110,121,122,126,132,134,136–139]). Most of the studies (n = 14) included a combination treatment, while only 6 reported data on monotherapy [platinum (1 study; [131]), taxanes (2 studies; [127,133]), 5-FU (1 study; [135]), alkylating agent (2 studies; [132,138]].
Chemotherapy is well-established in the treatment of patients with well-differentiated neuroendocrine tumours (NETs) arising from the pancreas (pNETs); however, its role in patients with gastrointestinal non-pancreatic NETs (non-pNETs) is uncertain. This systematic review assesses the evidence for the role of chemotherapy in well-differentiated non-pNET patients.
Eligible studies (identified using MEDLINE) were those reporting response and/or survival data for patients with well-differentiated non-pNETs receiving systemic chemotherapy. The primary end-point was overall-response (OR) rate; secondary end-points were progression-free survival (PFS), overall survival (OS), disease-stabilization (DS) and disease-control (DC) rates.
Of 6434 studies screened, 20 were eligible: one randomised phase III trial, 2 randomised phase II studies, 10 single-arm phase II trials and 7 retrospective analyses including a total of 264 patients (median of 11 patients per study, range 6–49); and employing multiple chemotherapy schedules. The mean “median PFS” and “median OS” were 16.9 months (95%-confidence interval (CI) 3.8–30.04) and 32.2 months (95%-CI 10.4–54.2), respectively. The non-weighted mean OR, DS and DC rates were 11.5% (95%-CI 5.8–17.2), 56.5% (95%-CI 38.1–74.9) and 70.7% (95%-CI 54.9–86.5), respectively. In studies including both pNETs and non-pNET patients, meta-analysis showed a lower OR-rate in the non-pNET patients when compared to pNETs [odds ratio (OR) 0.35 (95% CI 0.18–0.66)]; however significance was lost when high-risk bias studies were excluded in a sensitivity analysis [OR 0.45 (95% CI 0.19–1.07); p-value 0.07].
Studies were of evidence level-C with heterogeneous populations and treatments; and small patient numbers. Well-designed, prospective studies are needed to adequately evaluate the role of chemotherapy in this setting.
Neuroendocrine tumours - Medical therapy: Biological
2016, Best Practice and Research: Clinical Endocrinology and Metabolism
Citation Excerpt :
In 1983 Öberg published first data on the clinical efficacy of IFN-α in six patients with carcinoid syndrome [51]. Subsequently, various non-randomized, mainly retrospective trials of heterogeneous cohorts reported symptom control and biochemical response between 30–70% and 50–60%, respectively [52–56]. The randomized prospective trial by Kölby and colleagues compared monotherapy with octreotide (100–200 μg 3x/day) with combination treatment (octreotide plus IFN-α 3–5 MU 3/week) in a homogeneous population of patients with carcinoid syndrome [57].
Somatostatin analogues (SSA) are well established antisecretory drugs that have been used as first line treatment for symptomatic control in hormonally active neuroendocrine tumours (NET) for three decades. Both available depot formulations of SSA, long-acting repeatable (LAR) octreotide and lanreotide autogel, seem similarly effective and well tolerated, although comparative trials in NET have not been performed. The importance of SSA as antiproliferative treatment has been increasingly recognized during recent years. Two placebo-controlled trials demonstrated significant prolongation of progression free survival under SSA treatment. However, objective response as assessed by imaging is rare. Interferon-α (IFNα) also has antisecretory and antiproliferative efficacy in NET. Due to the less favourable toxicity profile it mainly has a role as add-on option in the refractory setting, especially in carcinoid syndrome patients.
Further studies are needed to evaluate the antiproliferative efficacy of the multiligand SSA pasireotide and the role of pegylated IFNα.

View all citing articles on Scopus

View full text

Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon

Abstract

Clin Chem Acta

Clinical antitumor activity and toxicity of streptozocin (NSC-8598)

Cancer

Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozocin

Cancer Treat Rep

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

Cancer Clin Trials

Cytotoxic treatment in patients with malignant carcinoid tumors; response to streptozocin alone or in combination with 5-FU

Acta Oncol

Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome

N Engl J Med

Treatment of malignant carcinoid tumors with human leucocyte interferon—long term results

Cancer Treat Rep

A silver nitrate stain for A2 cells in human pancreatic islets

Acta Soc Med Uppsala